Banner

What's New

Innovative resource for your improved understanding of
specialty diseases

Monthly Archives: July 2015

MDoutlook OncoPoll ASCO-EHA 2015 – CLL and Multiple Myeloma

MDoutlook is pleased to release the third report on the clinical impact of new data presented at ASCO and EHA 2015. This report includes analyses from 2 studies in hematologic malignancies involving more than 150 oncologists and hematologists with identified focus on Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM).

Our MD/PhD Disease Analyst Team reports:
CLL

  • Both the HELIOS and Complement 2 clinical trials will impact the CLL treatment landscape
    – Ibrutinib usage is expected to rise by 50% to 110% across all CLL subgroups in the next 6 months
    – Anti-CD20 mAb usage in CLL is slowly shifting from 1st generation rituximab to 2nd / 3rd generation ofatuzumab and obinutuzumab
  • Physicians have very high expectations for the BCL-2 Inhibitor venetoclax in CLL
    – The new PI3K inhibitors duvelisib and TGR-1202 are also positively viewed

Multiple Myeloma

  • The immune-oncology revolution has come to multiple myeloma with 2 new monoclonal antibodies: the anti-CS1 mAb elotuzumab and the anti-CD38 mAb daratumumab
  • Virtually all oncologists would use elotuzumab in at least some of their relapsed / refractory myeloma patients if it were commercially available today
    – 40% of respondents reported they would use it in 60% or more of their patients
    – Overall, ~50-60% of relapsed / refractory myeloma patients would receive it as treatment
  • Carfilzomib (Kd) is expected to become the preferred proteasome inhibitor over bortezomib (Vd) in the therapy of relapsed MM

Download your complimentary copy of the MDoutlook 2015 ASCO-EHA Syndicated CLL and MM OncoPoll Report  through the link.

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide meaningful, timely and relevant insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community. This is MDoutlook’s 8th consecutive year of syndicated research analyzing new data presented at large cancer meetings, and consists of more than 40 reports since 2008.

MDoutlook is disease intelligence redefined. Governed by top ThoughtLeaders and driven by in-house MD and PhD medical experts, MDoutlook® is powered by a proprietary, global cloud-based disease intelligence platform accessing 1M+ multi-disciplinary treaters of complex diseases, including cancer, hematology, auto-immune diseases.

Email or phone (+1.404.496.4136 / 888.3outlook) to discuss how MDoutlook can answer your disease intelligence needs.

MDoutlook OncoPoll ASCO 2015 – GI Cancers

MDoutlook proudly presents the second study on the clinical impact of new data presented at ASCO 2015. This OncoPoll™ includes analyses from 2 studies in Gastrointestinal Cancers involving more than 160 oncologists.

Our MD/PhD research team reports the following analysis highlights:
Non-CRC GI Cancers

  • Anti-PD-1 antibodies are expected to have a large impact for selected patients with Gastric, Esophageal and Hepatocellular Cancers
  • At current drug costs, only average value is placed on these agents in GI cancers (lower than what is seen for NSCLC)
  • 75% of the respondents expect the PEGH20 addition to have intermediate or high clinical impact on the treatment of pancreatic cancer
  • Regorafenib will be widely used in advanced G/GEJ cancers upon regulatory approval

Metastatic Colorectal Cancer

  • The immune checkpoint inhibitors (anti-PD-1/PD-L1) are going to have a very significant impact on the treatment landscape for MMR-deficient mCRC
    – Over a quarter of mCRC patients with this deficiency are expected to receive this treatment almost immediately
    – Most mCRC patients will now be tested for an MMR deficiency
  • At today’s prices, physicians see good value in using the anti-PD-1/PD-L1 antibodies for mCRC
  • Combining BRAF+/-MEK inhibitors with anti-EGFR antibodies is initially seen to have only a limited impact on the treatment of BRAF-mutated CRC

Download your complimentary copy of the MDoutlook 2015 ASCO Syndicated GI Cancers OncoPoll here.

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide meaningful, timely and relevant insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community.

MDoutlook is disease intelligence redefined. Governed by top ThoughtLeaders and driven by in-house MD and PhD medical experts, MDoutlook® is powered by a proprietary, global cloud-based disease intelligence platform accessing 1M+ multi-disciplinary treaters of complex diseases, including cancer, hematology, auto-immune diseases.

Email or phone (+1.404.496.4136 / 888.3outlook) to discuss how MDoutlook can answer your disease intelligence needs.